PCM
IGMS

Prelude Capital Management’s IGM Biosciences IGMS Stock Holding History

Prelude Capital Management’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-29,421
Closed -$244K – 1413
2023
Q4 		$244K Sell
29,421
-7,800
-21% -$45.3K 0.02% 843
2023
Q3 		$311K Buy
37,221
+17,546
+89% +$149K 0.02% 653
2023
Q2 		$182K Buy
+19,675
New +$220K 0.01% 857

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Prelude Capital Management's IGMS Position: Q1 2024 in Review

Prelude Capital Management sold out of IGM Biosciences (IGMS) in Q1 2024, closing a stake of 29,421 shares — an estimated $244K sold.

Prelude Capital Management first reported a position in IGMS in Q2 2023 and held it in 3 quarters. The position peaked at $311K in Q3 2023. 87 funds tracked by Wall St. Rank hold IGMS as of Q1 2024.

  • Prelude Capital Management reported no remaining IGM Biosciences position as of Q1 2024 after selling out during the quarter.
  • Prelude Capital Management sold 29,421 IGM Biosciences shares in Q1 2024, an estimated $244K.
  • Prelude Capital Management first reported a position in IGM Biosciences in Q2 2023 and held it in 3 quarters.
  • Prelude Capital Management's IGM Biosciences position peaked at $311K in Q3 2023.
  • 87 funds tracked by Wall St. Rank held IGM Biosciences as of Q1 2024.

Based on Prelude Capital Management's 13F filing for Q1 2024, filed 15 May 2024.